Diabetes Mellitus, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice.
|
23090186 |
2013 |
Insulin Resistance
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Impact of dietary fat quantity and quality on skeletal muscle fatty acid metabolism in subjects with the metabolic syndrome.
|
22658938 |
2012 |
Diabetes Mellitus, Experimental
|
0.500 |
Biomarker
|
disease |
RGD |
In vivo and in vitro effects of SREBP-1 on diabetic renal tubular lipid accumulation and RNAi-mediated gene silencing study.
|
19048273 |
2009 |
Insulin Resistance
|
0.500 |
Biomarker
|
phenotype |
RGD |
Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
|
17241878 |
2007 |
Diabetes Mellitus, Experimental
|
0.500 |
Biomarker
|
disease |
CTD_human |
Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets.
|
10900012 |
2000 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Critical evaluation of the DNA-methylation markers ABCG1 and SREBF1 for Type 2 diabetes stratification.
|
31169416 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results indicated that emodin could induce apoptosis in an SREBP1-dependent and SREBP1-independent manner in hepatocellular carcinoma cells.
|
31297058 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
And the inhibitor of SREBP1 and mTOR may help to prevent HCC in clinical NAFLD patients.
|
31409773 |
2019 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This observation suggested the negative role of SREBP-1 in clinical HCC prognosis.
|
31511501 |
2019 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, dietary BA enhanced the growth and alleviated liver fibrosis induced by a high starch diet to steatohepatitis/recovery symptom via improving glucose and lipid metabolism, which regulated by AKT/FOXO1 and cAMP/AMPK/SREBP1 pathway in largemouth bass.
|
31824338 |
2019 |
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study unveils an H19/PTBP1/sterol regulatory element-binding protein 1 feedforward amplifying signaling pathway to exacerbate the development of fatty liver.(Hepatology 2018;67:1768-1783).
|
29140550 |
2018 |
Fatty Liver
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Loss of Pgrmc1 increased mature SREBP-1 protein level, suggesting that induction of hepatic steatosis in Pgrmc1 KO mice might be triggered by de novo lipogenesis.
|
30356113 |
2018 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these data suggest that HSWE induces an intrinsic apoptosis, and reduced unsaturated fatty acids by blocking SREBP1 in hepatocellular carcinoma cells.
|
29702135 |
2018 |
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Coexpression of SREBP-1 and nuclear HDGF predicts poor prognosis for HCC.
|
30004626 |
2018 |
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Loss of Pgrmc1 increased mature SREBP-1 protein level, suggesting that induction of hepatic steatosis in Pgrmc1 KO mice might be triggered by de novo lipogenesis.
|
30356113 |
2018 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study unveils an H19/PTBP1/sterol regulatory element-binding protein 1 feedforward amplifying signaling pathway to exacerbate the development of fatty liver.(Hepatology 2018;67:1768-1783).
|
29140550 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
<b>Results</b>: Both SREBPs mRNA expression were significantly higher in patients with CAD and diabetes (p<0.001) and were identified as independent cardiovascular risk factor for coronary artery disease in patients with type-2 diabetes (SREBP-1: OR 1.7, 95%CI 1.1-2.5, p=0.02; SREBP-2: OR 1.6, 95%CI 1.2-3, p=0.02) and were independently associated with the presence of multivessel CAD, left main and anterior descending artery stenosis, and higher total and LDL cholesterol levels, and lower HDL cholesterol levels, in patients with CAD and diabetes.
|
28367087 |
2017 |
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
FK866 significantly promoted liver steatosis in the mice fed with HFD and hepatic lipid accumulation in vitro, accompanied by the increases of the expressions of lipogenic genes such as sterol regulatory element-binding protein 1 (SREBP1) and fatty acid synthase (FASN).
|
28449683 |
2017 |
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
The improvement of hepatic steatosis observed in DIO-treated mice was associated with a decrease in the hepatic content of SREBP-1, a transcription factor involved in de novo lipogenesis.
|
28557705 |
2017 |
Fatty Liver
|
0.400 |
Biomarker
|
disease |
BEFREE |
Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
|
28483554 |
2017 |
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinically, our data revealed that TIP30 expression significantly correlated with SREBP1 in patients with HCC and that a combination of TIP30 and SREBP1 is a powerful predictor of HCC prognosis.
|
28604762 |
2017 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The improvement of hepatic steatosis observed in DIO-treated mice was associated with a decrease in the hepatic content of SREBP-1, a transcription factor involved in de novo lipogenesis.
|
28557705 |
2017 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
|
28483554 |
2017 |
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
FK866 significantly promoted liver steatosis in the mice fed with HFD and hepatic lipid accumulation in vitro, accompanied by the increases of the expressions of lipogenic genes such as sterol regulatory element-binding protein 1 (SREBP1) and fatty acid synthase (FASN).
|
28449683 |
2017 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DNA methylation of cg18181703 (SOCS3), cg11024682 (SREBF1), and cg19693031 (TXNIP) was not associated with future T2D risk in subjects from the Botnia prospective study.
|
27148772 |
2016 |